RxDoctor Payments Data

Ryan Melchior, DO

Cardiovascular Disease · Midlothian, VANPI 1316267511

Payments from drug & device makers

$53,956in general payments, 2019–2025

Across 490 payments — averaging $110.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$24K
  • Angiodynamics, Inc.$19K
  • Abiomed$1K
  • AstraZeneca$959
  • Novartis$802
  • Amgen$739
  • plus $8K from 48 others

What the payments were for

  • Consulting fees$2,5305%
  • Speaking & faculty fees$19,20036%
  • Travel & lodging$1,4683%
  • Food & beverage$12,14823%
  • Education$680%
  • Other$18,54234%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,956 in reported general payments places this provider in the 85th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$858,584
Medicare patients
3,084
Services billed
12,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$272,976
EntrestoSacubitril/Valsartan106$115,772
XareltoRivaroxaban50$69,490
Repatha SureclickEvolocumab54$48,224
FarxigaDapagliflozin Propanediol56$46,942
Praluent PenAlirocumab25$17,123
BrilintaTicagrelor33$17,085
JardianceEmpagliflozin12$7,820
Atorvastatin Calcium463$3,499
Metoprolol Succinate259$2,731
Carvedilol343$2,577
Losartan Potassium248$2,366
Clonidine19$1,942
Amlodipine Besylate341$1,800
Rosuvastatin Calcium135$1,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$393$272,976274 claims
NovartisEntresto$802$115,772106 claims
Johnson & JohnsonXarelto$710$69,49050 claims
AstraZenecaFarxiga, Brilinta$959$64,02689 claims
Boehringer IngelheimJardiance$432$7,82012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →